Compare CURR & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CURR | EBS |
|---|---|---|
| Founded | 2013 | 1998 |
| Country | Singapore | United States |
| Employees | N/A | 900 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.2M | 349.2M |
| IPO Year | 2021 | 2006 |
| Metric | CURR | EBS |
|---|---|---|
| Price | $2.14 | $6.82 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 133.0K | ★ 1.0M |
| Earning Date | 11-10-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | ★ N/A | N/A |
| Revenue | $46,435,412.00 | ★ $742,900,000.00 |
| Revenue This Year | $12.39 | N/A |
| Revenue Next Year | N/A | $7.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.31 | $4.36 |
| 52 Week High | $5.08 | $14.06 |
| Indicator | CURR | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 31.72 | 53.16 |
| Support Level | $1.31 | $6.13 |
| Resistance Level | $2.30 | $7.05 |
| Average True Range (ATR) | 0.24 | 0.33 |
| MACD | -0.02 | 0.03 |
| Stochastic Oscillator | 4.26 | 62.55 |
Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It operates into two reportable segments, which are remittance services and sales of airtime, of which maximum revenue is generated from the Remittance segment. Geographically, the group generates the majority of its geographic revenue from Malaysia.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.